This cross-disease exploration reflects growing recognition of shared mitochondrial mechanisms and offers opportunities for developing more holistic therapeutic approaches
This synergistic potential with existing medications represents one of cerebrolysin most practical clinical applications
500 ng of peptides loaded on Evotip pure devices (Evosep) according to manufacturer protocol were separated using the pre-programmed 60 samples per day gradient on an 8 cm length 100 m ID capillary column (Evosep)
Parthasarathy, G
Addressing this gap, this review offers three integrated contributions: first, it positions ferroptosis as a convergent metabolic executioner across a broader spectrum of kidney diseasesencompassing AKI, DN, renal interstitial fibrosis, systemic lupus erythematosus (SLE) nephritis, autosomal dominant polycystic kidney disease (ADPKD), renal cell carcinoma (RCC), and contrast-induced nephropathy (CIN)while emphasizing cell type-specific vulnerabilities: tubular epithelial cells (susceptible via mitochondrial dysfunction), podocytes (via iron overload), and immune cells (e.g., neutrophils/macrophages in SLE nephritis) exhibit context-dependent ferroptosis regulation, governed by cell type-specific modulators [e.g., Nrf2 in tubules, heme oxygenase-1 (HO-1) in macrophages, and sirtuins in podocytes]
